Full Press Release Details
ANDOVER, Mass.,Aug. 25, 2025/PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the Morgan Stanley 23rdAnnual Global Healthcare Conference inNew YorkonMonday, September 8, 2025, at10:00 a.m. ESTand present at the Baird 2025 Global Healthcare Conference inNew YorkonTuesday, September 9, 2025, at12:15 p.m. EST.
Event: Morgan Stanley 23rdAnnual Global Healthcare ConferenceDate:Monday, September 8, 2025Time:10:00 a.m. EST
Event: Baird 2025 Global Healthcare ConferenceDate:Tuesday, September 9, 2025Time:12:15 p.m. EST
A live and archived webcast of the presentations will be available on the "Investors" section of the TransMedics website athttps://investors.transmedics.com/. The Company's standard investor presentation is also available through this link.
About TransMedics Group, Inc.TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered inAndover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Investor Contact:Brian JohnstonLaine Morgan332-895-3222[email protected]
SOURCE TransMedics Group, Inc.